Protocols
Adjuvant Treatment of Stage III and IV, BRAF mutated, fully resected Melanoma Using daBRAFenib and Trametinib
Adjuvant Therapy of High Risk Malignant Melanoma with High Dose Interferon (HDIFN) alpha-2b
Adjuvant Treatment of Resected Stage III – IV NED Melanoma Using Nivolumab
Adjuvant Treatment of Resected Stage III - IV NED Melanoma Using 4-Weekly Nivolumab
Adjuvant Treatment of Resected Stage III – IV NED Melanoma Using Pembrolizumab
First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab
Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab
Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab and Nivolumab
Treatment of Unresectable or Metastatic Melanoma Using Nivolumab
Treatment of Unresectable or Metastatic Melanoma Using 4-Weekly Nivolumab
Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab
Treatment of Unresectable or Metastatic Melanoma Using 6-Weekly Pembrolizumab
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Dabrafenib
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using daBRAFenib and Trametinib
Treatment of Advanced C-Kit Positive Melanoma Using iMAtinib
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Trametinib
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using vemURAFenib and cobimetinib
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Vemurafenib
Palliative Therapy for Malignant Melanoma with Brain Metastases Using Temozolomide
Therapy for Metastatic Malignant Melanoma Using High Dose Single Agent Dacarbazine (DTIC)
Topical Immunotherapy for In-Transit Melanoma Metastases, Cutaneous Lymphoma, Basal Cell Carcinoma Using Imiquimod
Topical Therapy for Skin Cancer with PDT (Photodynamic Therapy)
Treatment of Metastatic or Locally Advanced Basal Cell Carcinoma Using Vismodegib
Second-Line Treatment of Recurrent or Metastatic Merkel Cell Carcinoma Using Avelumab
Treatment of recurrent or metastatic Merkel cell carcinoma (MCC) with CISplatin and Etoposide
